Alnylam Pharmaceuticals, Inc. (ALNY) Down 4.6% — Time to Sell and Move Forward?
Alnylam Pharmaceuticals, Inc. (ALNY) is under pressure this Thursday, last trading at $235.38 on the NASDAQ. That is an $11.36 decline from the prior close of $246.74. The drop deepens a long slide for the stock, which now trades roughly 52.5% below its 52-week high of $495.55, a level reached on October 20, 2025. Losing more than half its value in under a year shows how sharply sentiment toward the RNAi leader has shifted since that peak.
With the session still open, roughly 738,644 shares have traded so far, against a 90-day average of about 1.63 million. Participation is running at less than half of a typical full day, so the decline is coming on moderate turnover at this point in the session.
Why Alnylam Pharmaceuticals, Inc. Price is Moving Lower
The selling looks company-specific rather than part of a broad biotech retreat. The SPDR S&P Biotech ETF (XBI) slipped just 0.14% on October 1. Large-cap Health Care names were softer but nowhere near ALNY's magnitude, with Merck & Co., Inc. (MRK) down 0.89% and Danaher Corporation (DHR) down 2.24%. The most plausible pressure is continued investor concern about Alnylam's transthyretin amyloidosis (ATTR) franchise and the clinical evidence needed to support its next leg of growth.
That concern has been building since August 28, when full Phase 3 results for AstraZeneca (AZN) and Ionis's (IONS) competing CARDIO-TTRansform drug missed the main endpoint. The trial posted a rate ratio of 0.89 (95% CI 0.73–1.09; p=0.277) and showed no observed added benefit among patients already taking stabilizer therapy. That outcome says nothing directly about Alnylam's approved drug. It does raise the bar for the company's future TTR program, particularly on demonstrating value in patients already on stabilizers.
The fundamental backdrop was already shaky heading into the fall. Alnylam's Q2 report on July 30 showed EPS of $1.84 against a $2.05 consensus, and revenue of $1.29 billion missed the $1.32 billion estimate even as it rose 66.9% year over year. The more consequential piece was guidance. Management cut 2026 TTR product-revenue guidance by $200 million at the midpoint, to a range of $4.2 billion to $4.5 billion, citing normalized U.S. second-line demand. On September 30, Cantor Fitzgerald reiterated its Neutral rating with a $325 price target, a measured stance that offers little near-term support. Attention now turns to initial ALN-HTT02 Huntington's disease data due October 23, which makes pipeline expectations an immediate focus for a stock that has lost much of its premium.
What is the Alnylam Pharmaceuticals, Inc. Rating - Should I Sell?
Weiss Ratings assigns ALNY a C rating. Current recommendation is Hold. The rating captures a company with a strong operating trajectory paired with a stock that has punished shareholders. A C rating does not signal a sale. It does reflect a risk/reward balance that calls for patience rather than aggressive buying, especially with TTR guidance recently lowered.
The strengths sit on the fundamental side. Alnylam is rated Excellent on the Growth Index, and the 66.86% revenue growth behind that rating is exceptional for a $34 billion company. That pace reflects how quickly its cardiomyopathy launch has scaled, even after the guidance trim. The Excellent rating on the Solvency Index matters just as much for a biotech still funding an expensive pipeline. With trailing EPS of $5.93, Alnylam is now self-funding, which leaves it far less exposed to dilution or financing risk than most RNAi and genetic-medicine peers.
Where the picture becomes more nuanced is efficiency. The Fair rating on the Efficiency Index may look odd next to a 100.70% ROE. That triple-digit figure says more about the thin equity base left behind by Alnylam's long history of losses than about outsized profitability. The 16.81% profit margin is the more telling number. It is respectable for a company only recently past breakeven, but modest for a business selling high-priced rare-disease therapies, and it explains why efficiency is not rated higher.
The market-facing indices are where the rating is held back. Alnylam is rated Weak on both the Total Return Index and the Volatility Index. A stock sitting more than 50% below its 52-week high has delivered painful returns over the measurement period. Today's 4.6% drop on TTR franchise worries, on a day the biotech ETF barely moved, illustrates why the Volatility Index is not rated higher. A forward P/E of 43.09 also leaves little room for further disappointment. Within the Health Care sector, Alnylam sits alongside Merck & Co., Inc. (MRK, C), Gilead Sciences, Inc. (GILD, C), and Pfizer Inc. (PFE, C), while it trails Thermo Fisher Scientific Inc. (TMO, C+), which carries a slightly better profile in Weiss's framework.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals (ALNY) is a Health Care company that pioneered RNA interference (RNAi) as a therapeutic modality. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company develops medicines that silence disease-causing genes at the messenger-RNA level. This approach lets it target conditions that conventional small molecules and antibodies have struggled to address.
The commercial portfolio is anchored by its transthyretin franchise. Onpattro (patisiran) and Amvuttra (vutrisiran) treat hereditary ATTR amyloidosis with polyneuropathy, and Amvuttra's expansion into ATTR cardiomyopathy has become the primary engine of the company's recent revenue growth. Beyond TTR, Alnylam markets Givlaari for acute hepatic porphyria and Oxlumo for primary hyperoxaluria type 1. It also earns royalties on Leqvio (inclisiran), the cholesterol-lowering therapy commercialized by Novartis.
Alnylam's competitive advantage rests on its platform. Its GalNAc conjugate delivery technology enables infrequent subcutaneous dosing, in some cases just a few times a year, which is a meaningful convenience edge in chronic disease. The company is extending that platform into larger markets and new tissues, including central nervous system programs such as ALN-HTT02 for Huntington's disease. Even so, its near-term fortunes remain heavily tied to ATTR, where it competes with stabilizer therapies and rival gene-silencing approaches from AstraZeneca and Ionis.
Investor Outlook
Alnylam Pharmaceuticals (ALNY) carries a Weiss Rating of C (Hold). Excellent growth and solvency are offset by a stock more than 50% off its highs, recently lowered TTR guidance, and lingering questions about the ATTR market. Investors should watch the October 23 ALN-HTT02 Huntington's data and whether U.S. demand trends support the $4.2 billion to $4.5 billion TTR revenue range in upcoming quarterly results. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--